At the end of the latest market close, Seneca Biopharma Inc. (SNCA) was valued at $1.89. In that particular session, Stock kicked-off at the price of $1.86 while reaching the peak value of $1.86 and lowest value recorded on the day was $1.69. The stock current value is $1.73.
Recently in News on April 2, 2021, Leading BioSciences Releases Video Message Highlighting Compelling Investment Thesis of Proposed Merger with Seneca Biopharma, Inc.. Video message explains the multiple benefits of the proposed merger and provides an overview of the substantial market opportunity for the combined company to be named Palisade Bio. You can read further details here
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Seneca Biopharma Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $2.6700 on 03/22/21, with the lowest value was $0.8700 for the same time period, recorded on 01/04/21.
Seneca Biopharma Inc. (SNCA) full year performance was 159.37%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Seneca Biopharma Inc. shares are logging -35.21% during the 52-week period from high price, and 245.93% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.50 and $2.67.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1281136 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Seneca Biopharma Inc. (SNCA) recorded performance in the market was 96.59%, having the revenues showcasing 60.19% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 30.10M, as it employees total of 5 workers.
Specialists analysis on Seneca Biopharma Inc. (SNCA)
During the last month, 0 analysts gave the Seneca Biopharma Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 1.2349, with a change in the price was noted +1.1649. In a similar fashion, Seneca Biopharma Inc. posted a movement of +206.14% for the period of last 100 days, recording 3,771,304 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for SNCA is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Trends and Technical analysis: Seneca Biopharma Inc. (SNCA)
Raw Stochastic average of Seneca Biopharma Inc. in the period of last 50 days is set at 42.68%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 34.27%. In the last 20 days, the company’s Stochastic %K was 41.30% and its Stochastic %D was recorded 41.68%.
Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 96.59%. Additionally, trading for the stock in the period of the last six months notably improved by 174.21%, alongside a boost of 159.37% for the period of the last 12 months. The shares increased approximately by 5.49% in the 7-day charts and went down by 45.38% in the period of the last 30 days. Common stock shares were driven by 60.19% during last recorded quarter.